Powell R, Rinkenbaugh A, Guo L, Cai S, Shao J, Zhou X
NPJ Breast Cancer. 2024; 10(1):37.
PMID: 38802426
PMC: 11130334.
DOI: 10.1038/s41523-024-00644-4.
Papakyriacou I, Kutkaite G, Rubies Bedos M, Nagarajan D, Alford L, Menden M
Nat Commun. 2024; 15(1):3581.
PMID: 38678024
PMC: 11055868.
DOI: 10.1038/s41467-024-47987-x.
Zhang S, Yu Q, Li Z, Zhao Y, Sun Y
Signal Transduct Target Ther. 2024; 9(1):85.
PMID: 38575611
PMC: 10995212.
DOI: 10.1038/s41392-024-01800-9.
Mao H, Lin X, Sun Y
Research (Wash D C). 2024; 6:0283.
PMID: 38434245
PMC: 10907026.
DOI: 10.34133/research.0283.
Wang T, Li X, Ma R, Sun J, Huang S, Sun Z
Int J Oncol. 2024; 64(4).
PMID: 38391033
PMC: 10919758.
DOI: 10.3892/ijo.2024.5627.
The CUL5 E3 ligase complex negatively regulates central signaling pathways in CD8 T cells.
Liao X, Li W, Zhou H, Rajendran B, Li A, Ren J
Nat Commun. 2024; 15(1):603.
PMID: 38242867
PMC: 10798966.
DOI: 10.1038/s41467-024-44885-0.
Neddylation is a novel therapeutic target for lupus by regulating double negative T cell homeostasis.
Zhang Y, Du L, Wang C, Jiang Z, Duan Q, Li Y
Signal Transduct Target Ther. 2024; 9(1):18.
PMID: 38221551
PMC: 10788348.
DOI: 10.1038/s41392-023-01709-9.
Deciphering the role of neddylation in tumor microenvironment modulation: common outcome of multiple signaling pathways.
Liu D, Che X, Wu G
Biomark Res. 2024; 12(1):5.
PMID: 38191508
PMC: 10773064.
DOI: 10.1186/s40364-023-00545-x.
Targeting NEDD8-activating enzyme for cancer therapy: developments, clinical trials, challenges and future research directions.
Fu D, Wang T
J Hematol Oncol. 2023; 16(1):87.
PMID: 37525282
PMC: 10388525.
DOI: 10.1186/s13045-023-01485-7.
NEDD8-activating enzyme inhibition potentiates the anti-myeloma activity of natural killer cells.
Petillo S, Sproviero E, Loconte L, Cuollo L, Zingoni A, Molfetta R
Cell Death Dis. 2023; 14(7):438.
PMID: 37460534
PMC: 10352239.
DOI: 10.1038/s41419-023-05949-z.
Small-molecule compounds inhibiting S-phase kinase-associated protein 2: A review.
Jing J, Rui L, Junyuan S, Jinfeng Y, Zhihao H, Weiguo L
Front Pharmacol. 2023; 14:1122008.
PMID: 37089937
PMC: 10113621.
DOI: 10.3389/fphar.2023.1122008.
Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T-cell responses in lymphoid neoplasia.
Wang X, Chen C, Vuong D, Rodriguez-Rodriguez S, Lam V, Roleder C
Leukemia. 2023; 37(6):1324-1335.
PMID: 37031300
PMC: 10244170.
DOI: 10.1038/s41375-023-01889-x.
Neddylation tunes peripheral blood mononuclear cells immune response in COVID-19 patients.
Serrano-Macia M, Lachiondo-Ortega S, Iruzubieta P, Goikoetxea-Usandizaga N, Bosch A, Egia-Mendikute L
Cell Death Discov. 2022; 8(1):316.
PMID: 35831294
PMC: 9277603.
DOI: 10.1038/s41420-022-01115-0.
Molecular alterations in human milk in simulated maternal nasal mucosal infection with live attenuated influenza vaccination.
Pannaraj P, da Costa-Martins A, Cerini C, Li F, Wong S, Singh Y
Mucosal Immunol. 2022; 15(5):1040-1047.
PMID: 35739193
PMC: 9225800.
DOI: 10.1038/s41385-022-00537-4.
The Ube2m-Rbx1 neddylation-Cullin-RING-Ligase proteins are essential for the maintenance of Regulatory T cell fitness.
Wu D, Li H, Liu M, Qin J, Sun Y
Nat Commun. 2022; 13(1):3021.
PMID: 35641500
PMC: 9156764.
DOI: 10.1038/s41467-022-30707-8.
Association Between Neddylation and Immune Response.
Zhu J, Chu F, Zhang M, Sun W, Zhou F
Front Cell Dev Biol. 2022; 10:890121.
PMID: 35602593
PMC: 9117624.
DOI: 10.3389/fcell.2022.890121.
The ubiquitin ligase Cul5 regulates CD4 T cell fate choice and allergic inflammation.
Kumar B, Field N, Kim D, Dar A, Chen Y, Suresh A
Nat Commun. 2022; 13(1):2786.
PMID: 35589717
PMC: 9120070.
DOI: 10.1038/s41467-022-30437-x.
Recycling and Reshaping-E3 Ligases and DUBs in the Initiation of T Cell Receptor-Mediated Signaling and Response.
Cammann C, Israel N, Slevogt H, Seifert U
Int J Mol Sci. 2022; 23(7).
PMID: 35408787
PMC: 8998186.
DOI: 10.3390/ijms23073424.
Neddylation and anti-tumor immunity.
Wang X, Best S, Danilov A
Oncotarget. 2021; 12(21):2227-2230.
PMID: 34676055
PMC: 8522835.
DOI: 10.18632/oncotarget.28019.
Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition.
Petillo S, Capuano C, Molfetta R, Fionda C, Mekhloufi A, Pighi C
Cell Death Dis. 2021; 12(9):836.
PMID: 34482362
PMC: 8418610.
DOI: 10.1038/s41419-021-04104-w.